ScoreWhy is Fredun Pharmaceuticals Ltd ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 36.42% and Operating profit at 59.04%
2
The company has declared Positive results for the last 8 consecutive quarters
- PBT LESS OI(Q) At Rs 11.25 cr has Grown at 54.96%
- PAT(Q) Highest at Rs 10.78 cr.
- DEBT-EQUITY RATIO(HY) Lowest at 0.80 times
3
With ROCE of 19.9, it has a Attractive valuation with a 3.2 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 203.99%, its profits have risen by 82.9% ; the PEG ratio of the company is 0.6
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.11% over the previous quarter and currently hold 44.17% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
5
Market Beating performance in long term as well as near term
- Along with generating 203.99% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Fredun Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fredun Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Fredun Pharma
203.99%
4.13
49.42%
Sensex
-10.52%
-0.81
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
36.42%
EBIT Growth (5y)
59.04%
EBIT to Interest (avg)
2.57
Debt to EBITDA (avg)
2.93
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
1.62
Tax Ratio
20.03%
Dividend Payout Ratio
2.11%
Pledged Shares
0
Institutional Holding
3.89%
ROCE (avg)
15.49%
ROE (avg)
12.48%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
33
Industry P/E
33
Price to Book Value
4.45
EV to EBIT
16.08
EV to EBITDA
14.74
EV to Capital Employed
3.21
EV to Sales
2.19
PEG Ratio
0.58
Dividend Yield
0.03%
ROCE (Latest)
19.94%
ROE (Latest)
13.65%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
PBT LESS OI(Q)
At Rs 11.25 cr has Grown at 54.96%
PAT(Q)
Highest at Rs 10.78 cr.
DEBT-EQUITY RATIO(HY)
Lowest at 0.80 times
NET SALES(Q)
Highest at Rs 213.05 cr
PBDIT(Q)
Highest at Rs 28.88 cr.
-13What is not working for the Company
OPERATING PROFIT TO INTEREST (Q)
Lowest at 1.99 times
INTEREST(Q)
Highest at Rs 14.49 cr
Loading Valuation Snapshot...
Here's what is working for Fredun Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 11.25 cr has Grown at 54.96%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 10.78 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 10.78 cr has Grown at 79.7%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 213.05 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 213.05 cr has Grown at 27.26%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 28.88 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.80 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Fredun Pharma
Interest - Quarterly
At Rs 14.49 cr has Grown at 37.35%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Operating Profit to Interest - Quarterly
Lowest at 1.99 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Interest - Quarterly
Highest at Rs 14.49 cr
in the last five quarters and Increased by 37.35 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
